Pharma Pulse 4/8/24: Cannabis Use in Oncology, J&J to Acquire Shockwave Medical & more

A Decade of Data Under the Belt

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses their drug Contrave and the data they have to show after a 10 years in the weight loss/obesity space.

Navigating the Landscape of Cannabis Use in Oncology

Despite being a Schedule I drug, cannabis is increasingly used in oncology for symptom management, although data remains limited.

China Is Targeting US Voters and Taiwan With AI-Powered Disinformation

Findings from Microsoft and others shed light on Beijing’s expanding covert influence operations

Johnson & Johnson to Acquire Shockwave Medical

Johnson & Johnson and Shockwave Medical, Inc. announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.

Cencora on LinkedIn:

VP of Reimbursement & Policy Insights Corey Ford recently spoke with Pharmaceutical Commerce Magazine about his predictions for the future of the Inflation Reduction Act, as well as his upcoming speaking engagement at the 2024 PAP Conference.

Learn more about how Corey views the future of pharma: https://ow.ly/4vex50R8AIN

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs